Company profile for Liminatus Pharma

Liminatus Pharma

NEW Drugs in Dev: 2

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

Contact Supplier

AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

Contact Supplier

Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

Contact Supplier

Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

Contact Supplier

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Contact Supplier

pharmacompass-2-m-2026-04-20

Contact Supplier

VIRTUAL BOOTH
CONTACT DETAILS
Google Map, LinkedIn, Emails...

DIGITAL CONTENT

11 News #PharmaBuzz

media
11 News #PharmaBuzz

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

The focus behind the incorporation of our company is to develop (from clinical trials and FDA approvals through to manufacturing and sales) solid tumor cancer CAR-Ts that treat metastatic GI cancers by using GCC CAR-T therapies. To achieve this goal, we have obtained a license for all GCC CAR-T-related patents and know-hows from Targeted Diagnostics & Therapeutics, Inc. (TDT), and our merger with Viral Gene, Inc., a company...

The focus behind the incorporation of our company is to develop (from clinical trials and FDA approvals through to manufacturing and sales) solid tumor cancer CAR-Ts that treat metastatic GI cancers by using GCC CAR-T therapies. To achieve this goal, we have obtained a license for all GCC CAR-T-related patents and know-hows from Targeted Diagnostics & Therapeutics, Inc. (TDT), and our merger with Viral Gene, Inc., a company that develops virus-based cancer immunotherapeutics, will help position us as a leader in GCC CAR-T therapeutics.

PEGS Boston SummitPEGS Boston Summit

Not Confirmed

Not Confirmed

11 May-15 November, 2026

Massachusetts, U.S.A
DIA Global Annual Meet...DIA Global Annual Meeting

Not Confirmed

Not Confirmed

14-18 June, 2026

Philadelphia, U.S.A
Discovery EuropeDiscovery Europe

Not Confirmed

Not Confirmed

15-16 June, 2026

Berlin, Germany

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown

United_States_of_America Flag

Country

Country

U.S.A

Address

Address

6 Centerpointe Drive Suite 625 La Palma, CA 90623

Telephone

Telephone

Email

enquiries@pharmacompass.com

Client Website

Website

https://www.liminatuspharma.com/

Linkedin

youtube

YouTube

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

Liminatus Pharma Closes $1.9M Warrant Exercise Transaction

03 Jun 2026

// GLOBENEWSWIRE

Liminatus Pharma Announces Nasdaq Delisting Notification

21 May 2026

// GLOBENEWSWIRE

Struggling Liminatus Acquires CAR-T Pharma InnocsAI for $320M

21 May 2026

// FIERCE BIOTECH

Liminatus Pharma Announces Phase 1 Trial of IBA101, CD47 Antibody

17 Mar 2026

// GLOBENEWSWIRE

Liminatus Announces Pricing of $4.0 Million Public Offering

17 Feb 2026

// GLOBENEWSWIRE

Liminatus Pharma Inks $30M Equity Deal With Capital Trust Group

30 Oct 2025

// GLOBENEWSWIRE

Drugs in Development

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Market Place

Home

Menu

Post Enquiry

Market Place

Search